Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in innovative cancer treatments, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event, set to take place in Miami Beach, FL, will feature a fireside chat with Arcus' management team on June 12th, 2024, at 10:00am ET. A live webcast of the discussion will be accessible via the 'Investors & Media' section of the company's website, with a replay available post-event.

Positive

• Arcus Biosciences' participation in a high-profile event like the Goldman Sachs Global Healthcare Conference can increase visibility and investor interest.
• The fireside chat offers an opportunity for management to share strategic insights and upcoming milestones directly with investors.
• Providing a live webcast and replay ensures broader accessibility and engagement from the investor community.

Negative

• The announcement lacks specific financial updates or clinical data, which may leave investors wanting more substantial information.
• There is no mention of new product developments or partnerships, which could be a concern for those looking for fresh growth catalysts.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45^th Annual Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Wednesday, June 12^th, 2024 at 10:00am ET.

A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606990218/en/

Investor Inquiries

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

When will Arcus Biosciences participate in the Goldman Sachs 45th Annual Global Healthcare Conference?

Arcus Biosciences will participate on June 12th, 2024, at 10:00am ET.

How can I watch the Arcus Biosciences fireside chat at the Goldman Sachs Healthcare Conference?

A live webcast will be available on the 'Investors & Media' section of the Arcus Biosciences website, with a replay accessible post-event.

What is the focus of Arcus Biosciences?

Arcus Biosciences specializes in developing differentiated molecules and combination therapies for cancer treatment.